Cube Labs SpA

Cube Labs SpA FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Cube Labs SpA (CUBE.MI) as of Oct 27, 2026 is -57,814.48 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 290.41 % — a change of -20,007.71% (lower).

FCF Conversion

-57,814.48 %

YoY

-20,007.71%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Cube Labs SpA is 2025 -57,814.48 % . FCF Conversion Rate (FCF/EBITDA) of Cube Labs SpA was 2024 290.41 % . It decreases by -20,007.71% lower compared to the previous year.

The Cube Labs SpA FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2020
-226.59 EUR
Jan 1, 2021
-177.65 EUR
Jan 1, 2022
1,986.44 EUR
Jan 1, 2023
465.75 EUR
Jan 1, 2024
290.41 EUR
Jan 1, 2025
-57,814.48 EUR
The Cube Labs SpA FCF Conversion history
YEARFCF ConversionYoY
-57,814.48 %-20,007.71%
290.41 %-37.65%
465.75 %-76.55%
1,986.44 %-1,218.15%
-177.65 %-21.60%
-226.59 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cube Labs SpA Stock analysis

What does Cube Labs SpA do? Cube Labs SpA generates revenue through healthcare technology services, focusing on creating and supporting companies from the R&D stage. The firm provides entrepreneurial and operational support for healthcare management and technology solutions, targeting global markets. It promotes and implements scientific research results in human health, biotechnology, and nanotechnology, serving clients seeking innovative healthcare technology integration. The company operates with a lean team of two full-time employees, leveraging its expertise in translating research into practical applications. Cube Labs SpA's business model centers on bridging the gap between scientific research and market-ready healthcare technology. By offering tailored support for startups in the healthcare sector, the company helps clients navigate the complexities of R&D commercialization. Its global operations allow it to serve clients across different regions, capitalizing on the increasing demand for advanced healthcare solutions. The firm's revenue streams are derived from its specialized services in healthcare technology development and implementation. The company's primary clients are healthcare technology startups and established firms looking to integrate scientific research into their operations. Cube Labs SpA supports these clients through its expertise in biotechnology and nanotechnology applications, delivering customized solutions that address specific market needs. With a focus on operational support and entrepreneurial guidance, the firm helps clients accelerate their time-to-market for innovative healthcare products. Cube Labs SpA is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cube Labs SpA stock

FCF Conversion Rate (FCF/EBITDA) of Cube Labs SpA is -57,814.48 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Cube Labs SpA changed from 290.41 % to -57,814.48 %, representing a -20,007.71% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Cube Labs SpA since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Cube Labs SpA with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Cube Labs SpA

All Key Metrics — Cube Labs SpA